{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:40:06Z","timestamp":1775104806299,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04687-7","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:48:07Z","timestamp":1762328887000},"page":"5515-5525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of serum tumor markers in assessing the efficacy of TP (Paclitaxel plus Carboplatin) chemotherapy combined with trastuzumab and pertuzumab dual target therapy in HER2-positive breast cancer"],"prefix":"10.1007","volume":"399","author":[{"given":"Lei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengqiang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jixin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"issue":"5","key":"4687_CR1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11864-023-01068-1","volume":"24","author":"C Corti","year":"2023","unstructured":"Corti C, Giugliano F (2023) HER2-low breast cancer: a new subtype? Curr Treat Options Oncol 24(5):468\u2013478","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"4687_CR2","first-page":"e39780","volume":"15","author":"F Fazal","year":"2023","unstructured":"Fazal F, Bashir MN, Adil ML et al (2023) Pathologic complete response achieved in early-stage HER2-positive breast cancer after neoadjuvant therapy with trastuzumab and chemotherapy vs. trastuzumab, chemotherapy, and pertuzumab: a systematic review and meta-analysis of clinical trials. Cureus 15(5):e39780","journal-title":"Cureus"},{"issue":"1","key":"4687_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.adengl.2019.05.021","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermo-Sifiliogr\u00e1ficas (English Edition) 112(1):90\u201392","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas (English Edition)"},{"key":"4687_CR4","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.12659\/MSM.896563","volume":"22","author":"Y Fu","year":"2016","unstructured":"Fu Y, Li H (2016) Assessing clinical significance of serum CA15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: a meta-analysis. Med Sci Monit 22:3154\u20133162","journal-title":"Med Sci Monit"},{"issue":"2","key":"4687_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5937\/jomb0-45192","volume":"43","author":"J Geng","year":"2024","unstructured":"Geng J, Jinli S, Guo W, Li H, Dan Y, Gao Y (2024) Expression and clinical significance of CA125, CA153 and CEA in nipple discharge of breast cancer patients. J Med Biochem 43(2):234\u2013242","journal-title":"J Med Biochem"},{"issue":"10074","key":"4687_CR6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","volume":"389","author":"N Harbeck","year":"2017","unstructured":"Harbeck N, Gnant M (2017) Breast cancer. Lancet 389(10074):1134\u20131150","journal-title":"Lancet"},{"key":"4687_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.33393\/jcb.2022.2446","volume":"11","author":"D Hasan","year":"2022","unstructured":"Hasan D (2022) Diagnostic impact of CEA and CA 15\u20133 on chemotherapy monitoring of breast cancer patients. J Circ Biomarkers 11:57\u201363","journal-title":"J Circ Biomarkers"},{"issue":"10371","key":"4687_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP (2023) Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-breast03, a randomised, open-label, phase 3 trial. Lancet 401(10371):105\u2013117","journal-title":"Lancet"},{"issue":"2","key":"4687_CR9","first-page":"158","volume":"32","author":"ZF Jiang","year":"2010","unstructured":"Jiang ZF, Shao ZM, Xu BH (2010) Diagnosis and treatment of HER-2-positive breast cancer: expert consensus of the Chinese Anti-Cancer Association. Zhonghua Zhong Liu Za Zhi [chinese Journal of Oncology] 32(2):158\u2013160","journal-title":"Zhonghua Zhong Liu Za Zhi [chinese Journal of Oncology]"},{"issue":"4","key":"4687_CR10","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1245\/s10434-020-09480-9","volume":"28","author":"RA Leon-Ferre","year":"2021","unstructured":"Leon-Ferre RA, Hieken TJ, Boughey JC (2021) The landmark series: neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer. Ann Surg Oncol 28(4):2111\u20132119","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4687_CR11","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12282-020-01058-3","volume":"27","author":"J Li","year":"2020","unstructured":"Li J, Liu L, Feng Z et al (2020) Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer 27(4):621\u2013630","journal-title":"Breast Cancer"},{"issue":"6","key":"4687_CR12","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ccell.2023.04.008","volume":"41","author":"MJM Magbanua","year":"2023","unstructured":"Magbanua MJM, Brown Swigart L, Ahmed Z et al (2023) Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell 41(6):1091-1102.e1094","journal-title":"Cancer Cell"},{"key":"4687_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123797","author":"A Mesquita","year":"2020","unstructured":"Mesquita A, Costa JL (2020) Utility of circulating tumor DNA in different clinical scenarios of breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12123797","journal-title":"Cancers (Basel)"},{"issue":"10","key":"4687_CR14","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.annonc.2021.06.024","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Ciruelos E, Schneeweiss A (2021) Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol 32(10):1245\u20131255","journal-title":"Ann Oncol"},{"issue":"8","key":"4687_CR15","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E (2023) Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med 29(8):2110\u20132120","journal-title":"Nat Med"},{"issue":"1","key":"4687_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227356","volume":"15","author":"A Perrier","year":"2020","unstructured":"Perrier A, Boelle PY, Chr\u00e9tien Y et al (2020) An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies. PLoS ONE 15(1):e0227356","journal-title":"PLoS ONE"},{"issue":"13","key":"4687_CR17","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.20.01204","volume":"39","author":"M Piccart","year":"2021","unstructured":"Piccart M, Procter M, Fumagalli D (2021) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years\u2019 follow-up. J Clin Oncol 39(13):1448\u20131457","journal-title":"J Clin Oncol"},{"issue":"4","key":"4687_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1136\/jcp-2022-208632","volume":"76","author":"EA Rakha","year":"2023","unstructured":"Rakha EA, Tan PH, Quinn C, Provenzano E, Shaaban AM, Deb R (2023) UK recommendations for HER2 assessment in breast cancer: an update. J Clin Pathol 76(4):217\u2013227","journal-title":"J Clin Pathol"},{"key":"4687_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340:c332","journal-title":"BMJ"},{"issue":"3","key":"4687_CR20","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143\u2013e152","journal-title":"Lancet Oncol"},{"issue":"4","key":"4687_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21(4):519\u2013530","journal-title":"Lancet Oncol"},{"issue":"10","key":"4687_CR22","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/S1470-2045(18)30481-9","volume":"19","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Hoff PM, Shen L et al (2018) Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19(10):1372\u20131384","journal-title":"Lancet Oncol"},{"issue":"1","key":"4687_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1470-2045(20)30536-2","volume":"22","author":"AR Tan","year":"2021","unstructured":"Tan AR, Im SA, Mattar A et al (2021) Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol 22(1):85\u201397","journal-title":"Lancet Oncol"},{"issue":"8","key":"4687_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Viale G, Press MF (2023) Esmo expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol 34(8):645\u2013659","journal-title":"Ann Oncol"},{"issue":"7","key":"4687_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1200\/JOP.18.00206","volume":"14","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M (2018) HER2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update summary. J Oncol Pract 14(7):437\u2013441","journal-title":"J Oncol Pract"},{"issue":"5","key":"4687_CR26","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H (2022) Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J 135(5):584\u2013590","journal-title":"Chin Med J"},{"issue":"1","key":"4687_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10549-022-06770-6","volume":"197","author":"XF Xie","year":"2023","unstructured":"Xie XF, Zhang QY, Huang JY et al (2023) Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial. Breast Cancer Res Treat 197(1):93\u2013101","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4687_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02398-w","volume":"19","author":"J Zhang","year":"2021","unstructured":"Zhang J, Huang Y, Chen J, Wang X, Ma H (2021) Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer. World J Surg Oncol 19(1):284","journal-title":"World J Surg Oncol"},{"key":"4687_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cca.2021.08.027","volume":"523","author":"J Zhang","year":"2021","unstructured":"Zhang J, Wei Q, Dong D, Ren L (2021) The role of TPsS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. Clin Chim Acta 523:19\u201325","journal-title":"Clin Chim Acta"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04687-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:13:51Z","timestamp":1775099631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04687-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4687"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04687-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval was granted by the\u00a0Institutional Review Board and Human Research Ethics Committee at Xijing Hospital, Air Force Medical University. All participants provided written informed consent before study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}